Substituted aromatic compounds and pharmaceutical uses thereof

Abstract

The present invention relates to substituted aromatic compounds of Formula I and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds in the prevention and/or treatment of various diseases and conditions in subjects, including the prevention or treatment of (i) blood disorders, (ii) renal disorders, a nephropathies, or renal disorder complications; (iii) inflammatory-related diseases; and/or (iv) oxidative stress related disorders.

The invention claimed is: 
     
       1. A method for treating anemia and/or leukopenia by stimulating production and/or inhibiting the decrease of normal leukocytes and/or normal erythrocytes in a patient in need thereof, comprising administering to the patient a pharmacologically effective amount of a compound represented by Formula II: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein: 
         n is 1; 
         Q is C 1 -C 2  alkyl optionally substituted with one R a  substituent; 
         R 1  is straight chain C 5  alkyl, C 6  alkyl, C 5 -C 6  alkenyl, or C 5 -C 6  alkynyl; 
         R 2  is H, halogen, haloalkyl, OR b , SR b , or NR c R d ; 
         R 3  is H, halogen, haloalkyl, straight chain C 1 -C 4  alkyl, OR b , SR b , or NR c R d ; 
         R 4  is H, halogen, haloalkyl, C 1 -C 4  alkyl, OR b , SR b , or NR c R d ; 
         R 5  is H or OR b ; 
         R a  is OR b , SR b , or NR c R d ; 
         R b  is H; and 
         R c  and R d  are independently chosen from: H and C 1 -C 4  alkyl. 
       
     
     
       2. The method of  claim 1 , wherein R 1  is straight chain C 5  alkyl, C 6  alkyl, or C 5 -C 6  alkenyl; and R 2  is H, halogen, haloalkyl, or OR b . 
     
     
       3. The method of  claim 1 , wherein R 3  is independently chosen from: H, halogen, haloalkyl, straight chain C 1 -C 4  alkyl, and OR 6 ; and R 4  is independently chosen from: H, halogen, haloalkyl, C 1 -C 4  alkyl, and OR b . 
     
     
       4. The method of  claim 1 , wherein R a  is OR b . 
     
     
       5. The method of  claim 1 , wherein the pharmaceutically acceptable salt is a base addition salt, and the base addition salt is a metal counterion, the metal counterion is sodium, magnesium, calcium, potassium or lithium. 
     
     
       6. The method of  claim 5 , wherein the metal counterion is sodium. 
     
     
       7. The method of  claim 1 , wherein the compound is selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         and other pharmaceutically acceptable salts thereof and the acid form thereof. 
       
     
     
       8. The method of  claim 7 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
     
     
       9. The method of  claim 1 , wherein the method is for treating anemia. 
     
     
       10. The method of  claim 9 , wherein the administration of said compound stimulates erythropoiesis in the patient. 
     
     
       11. A method for treating a blood disorder selected from anemia, and leukopenia in a patient in need thereof, comprising administering to the patient a pharmacologically effective amount of a compound selected from 
       
         
           
           
               
               
           
         
       
       and other pharmaceutically acceptable salts thereof and the acid form thereof. 
     
     
       12. The method of  claim 11 , wherein the pharmaceutically acceptable salt is a base addition salt. 
     
     
       13. The method of  claim 12 , wherein the base addition salt is a metal counterion. 
     
     
       14. The method of  claim 13 , wherein the metal counterion is sodium, magnesium, calcium, potassium or lithium. 
     
     
       15. The method of  claim 14 , wherein the metal counterion is sodium. 
     
     
       16. The method of  claim 11 , wherein the administration of said compound stimulates hematopoiesis and/or erythropoiesis in the patient. 
     
     
       17. The method of  claim 1 , wherein the method is for treating leukopenia. 
     
     
       18. The method of  claim 17 , wherein the leukopenia is neutropenia. 
     
     
       19. The method of  claim 17 , wherein the administration of said compound stimulates hematopoiesis in the patient. 
     
     
       20. The method of  claim 1 , wherein the anemia and/or leukopenia is caused by chemotherapy.